Abstract: Pulse cyclophosphamide (PCP) is a well established method for the treatment of lupus nephritis. PCP seems to produce better results, and lesser side effects, than oral cytotoxic drugs. We present here, our experience with this method, in 51 patients. All patients had a WHO type IV histological lesion, on light microscopy. Proteinuria, hematuria, leucocyturia, casts, BUN, creatinine, and blood pressure were measured before starting PCP and after each one. The first ...
Pulse Cyclophosphamide (PCP) in ophthalmologic manifestations of Behcet's disease (BD).
Abstract: PCP as lg/m2/body surface was given once per month, with 0.5 mg prednisolone/kg/day, to 155 patients with sever posterior uveitis (PU) and/ or retinal vasculitis (RV). A Disease Activity Index (DAI), based upon the inflammatory state of the eye, was calculated for each section of each eye before the first PCP and then after each PCP. When a remission was obtained the gap between PCP was increased gradually to 2, ...
SLE in Iran, Analysis of 503 cases.
Abstract: Systemic Lupus Erythematosus (SLE) is not a rare disease in Iran. In the past 13 years, we have seen 503 cases, with the following characteristics. Females 87%, males 13%, mean age 23 years (SD=11.25). Clinical manifestations were as follow: General manifestation in 57% (fever 52%, fatigue 39%, lack of appetite 18%, weight loss 36%). Mucocutaneous manifestations in 80% (malar rash 67%, discoid lesions 9%, photosensitivity 45%, alopecia 9%, Raynaud's phenomenon ...